At the Intersection of Science and Law

Follow At the Intersection of Science and Law
Share on
Copy link to clipboard

In DLA Piper’s At the Intersection of Science and Law podcast, members of the firm’s Life Sciences team explore the connection between science and the law in areas that include AI and drug discovery, mRNA technology, and the regulatory implications of new drugs and devices.

DLA Piper


    • Nov 15, 2024 LATEST EPISODE
    • infrequent NEW EPISODES
    • 28m AVG DURATION
    • 14 EPISODES


    More podcasts from DLA Piper

    Search for episodes from At the Intersection of Science and Law with a specific topic:

    Latest episodes from At the Intersection of Science and Law

    Revolutionizing Clinical Trials: A discussion on diversity and patient-centric approaches

    Play Episode Listen Later Nov 15, 2024 29:38


    In this episode, Quest Diagnostics' Adam Donat is joined by DLA Piper's Kirsten Axelsen, Rachel Portman, and Jae Kim to discuss the increasing complexity and cost of clinical trials, new FDA guidance, innovative trial designs and tools, and what's expected in the new year.See omnystudio.com/listener for privacy information.

    Life sciences companies and the risks posed by the mifepristone litigation

    Play Episode Listen Later May 19, 2023 33:18


    In this episode, a cross-disciplinary team of FDA regulatory lawyers and life sciences litigators discuss the implications of the mifepristone litigation for life sciences companies as it pertains to citizen petitions, FDA approvals, and strategies manufacturers might consider going forward.See omnystudio.com/listener for privacy information.

    Trade secrets protection in the life sciences sector

    Play Episode Listen Later Apr 12, 2023 21:23


    DLA Piper's Roberto Valenti and Ray Miller discuss trade secrets protection in the US and Europe and the peculiarities within the life sciences sector. Our speakers provide pragmatic approaches and suggestions on how to manage trade secrets for both pharmaceutical companies and medical device manufacturers.See omnystudio.com/listener for privacy information.

    Cross-border considerations for privacy in clinical trials

    Play Episode Listen Later Feb 6, 2023 18:19


    Published in Chambers Expert Focus. With the recent publication of our Cross-border Guide to Clinical Trials and Privacy, James Clark, Paula Gonzalez de Castejón and David Kopans discuss ongoing and developing EU and US perspectives on privacy considerations with respect to cross-border clinical trials.See omnystudio.com/listener for privacy information.

    Global Life Sciences Supply Chain Insights

    Play Episode Listen Later Nov 3, 2022 27:36


    Published in Chambers Expert Focus. Lauren Murdza and Richard Taylor share their insights on supply chain issues in the life sciences sector in the latest episode of At the Intersection of Science and Law.See omnystudio.com/listener for privacy information.

    AI risk assessments: Future-proofing your innovation when rules can change mid-game

    Play Episode Listen Later Sep 6, 2022 24:43


    In this episode, DLA Piper partner Danny Tobey is joined by Aviva Wein, Assistant General Counsel at Johnson & Johnson, to discuss how medical device and pharmaceutical companies are future-proofing their innovations in artificial intelligence as new regulations and risks arise.See omnystudio.com/listener for privacy information.

    The rise of telehealth amid the COVID-19 pandemic

    Play Episode Listen Later Jun 1, 2022 38:13


    Kristi Kung is joined by Greg Bodulovic to discuss digital health and its rise during the COVID-19 pandemic as well as advancements in technology that address healthcare access. See omnystudio.com/listener for privacy information.

    Advising the advisor: Tips for navigating the life sciences and regulatory environment

    Play Episode Listen Later Apr 18, 2022 31:00


    In this episode, DLA Piper managing partner Emilio Ragosa is joined by Kevin Sheridan, Joint Global Head of Healthcare Investment Banking at Jefferies LLC, to discuss the importance of advisors having an understanding of the life sciences industry in order to provide value-added advice on transactions, including public offerings and M&A. See omnystudio.com/listener for privacy information.

    The moral imperative: Balancing innovation, regulation and prescription drug availability

    Play Episode Listen Later Mar 21, 2022 30:31


    In this episode, DLA Piper's Jim Greenwood and Geoff Levitt are joined by Peter Kolchinsky, founding Partner and Portfolio Manager at RA Capital, to discuss the importance of – and complications in – balancing biopharmaceutical innovation, industry regulations and prescription drug availability. See omnystudio.com/listener for privacy information.

    Incentivizing diverse representation in clinical trials

    Play Episode Listen Later Mar 2, 2022 22:40


    Diverse representation in clinical trials is critical in achieving greater equity and better healthcare outcomes. In this episode, DLA Piper's Kirsten Axelsen and Sarah Schick are joined by Shazia Ahmad, Senior Director and Head of Patient and Physician Services at UBC, to discuss the importance of regulatory incentives to drive racial and ethnic diversity in clinical trials. See omnystudio.com/listener for privacy information.

    The crossroad of science and law

    Play Episode Listen Later Dec 16, 2021 26:10


    In this episode, DLA Piper's Lucas Przymusinski and Raymond Williams are joined by Michael King, Vice President and Associate General Counsel at Jazz Pharmaceuticals, to discuss the benefits of medical and science backgrounds when litigating matters for pharmaceutical and medical device companies.

    Social media's impact on the life sciences industry

    Play Episode Listen Later Nov 8, 2021 34:41


    In this episode, DLA Piper's Chris Campbell and Jody Rhodes are joined by Sarah Heineman, Senior Assistant General Counsel at Bayer, to discuss how social media affects the public's view of medicine and science and how that in turn impacts the life sciences industry, including litigation.

    Understanding AI and its use in drug discovery

    Play Episode Listen Later Oct 5, 2021 31:40


    DLA Piper partners Ellen Scordino and Susan Krumplitsch are joined by Duane Valz, General Counsel of Insitro, to discuss how machine learning is being used to generate and leverage data for the development of better medicines.

    mRNA technology and the COVID-19 vaccine: A conversation with Pfizer's Kathy Fernando

    Play Episode Listen Later Sep 3, 2021 26:18


    For decades, scientists have studied the seemingly endless possibilities of custom-made messenger RNA, or mRNA. Kathy Fernando, Head Vice President, Worldwide of Clinical Operations at Pfizer, spent her early bench science career working with mRNA technology and had a front row seat to the creation of the COVID-19 vaccine. In this episode, DLA Piper's Dr. Lisa Haile talks with Dr. Fernando about the study of mRNA and how COVID-19 catalyzed its advancement.

    Claim At the Intersection of Science and Law

    In order to claim this podcast we'll send an email to with a verification link. Simply click the link and you will be able to edit tags, request a refresh, and other features to take control of your podcast page!

    Claim Cancel